A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

UBS lowered the firm’s price target on Pfizer (PFE) to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Check the time stamp on this data. Updated AI-Generated Signals for Pfizer Inc. (PFE) available here: PFE.

智通财经APP获悉，美国食品和药物管理局(FDA)表示，葛兰素史克(GSK.US)和辉瑞(PFE.US)生产的一种常见呼吸道病毒疫苗必须附有警告，说明这些疫苗可能会增加一种罕见的神经系统副作用的风险，这种副作用可能导致瘫痪。该机构在周二发布的一份安全 ...

At the urging of the group Do No Harm, a 2-1 court panel revisted a decision it issued last year holding the organization ...